Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmunityBio, Inc. (Nasdaq: IBRX) on December 10, 2025. The report discloses a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the appointment of a director and associated compensation terms.
Material Changes
The primary material change reported is the appointment of Bruce Wendel to the Board of Directors, effective December 12, 2025. Mr. Wendel has been determined to qualify as an "independent" director under Nasdaq and SEC rules. His term will expire at the Company's 2026 annual meeting of stockholders.
Management Commentary, Risks, and Compensation
Management has outlined the following compensation package for Mr. Wendel under the Company's Amended and Restated Director Compensation Policy:
- Cash Compensation: $50,000 annually for service as a Board member.
- Equity Compensation: An initial award of stock options with a Black-Scholes value of $300,000 on the effective date.
- Vesting Schedule: The Initial Award vests one-third on each anniversary of the effective date, contingent on continued service. Full vesting occurs immediately prior to a Change in Control.
- Expenses: Reimbursement for reasonable, customary, and documented travel expenses to Board meetings.
Mr. Wendel executed the Company's standard indemnification agreement. The filing states there are no undisclosed arrangements regarding his selection and no transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Mr. Wendel's board appointment (December 12, 2025).
- Confirm the total value of the initial stock option award ($300,000 Black-Scholes value).
- Review the vesting terms, specifically the one-third annual vesting and Change in Control acceleration provisions.
- Check the Company's 2025 Equity Incentive Plan for details on the option grant mechanics.
- Monitor the 2026 annual meeting of stockholders for the expiration of Mr. Wendel's initial term.